Daniel J Landsburg, MD

faculty photo
Associate Professor of Clinical Medicine (Hematology-Oncology)
Medical Director, Infusion Services, Hospital of the University of Pennsylvania
Physician Leader, Hematology/Oncology Fellowship Quality Improvement, Hospital of the University of Pennsylvania
Faculty mentor, Department of Medicine residency Quality Improvement Track, Hospital of the University of Pennsylvania
Physician Leader, Oncology Clinical Effectiveness Team, University of Pennsylvania
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-182
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-615-7361
Fax: 215-615-5888
University of Pennsylvania, 2004.
Temple University School of Medicine, 2008.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

Non-Hodgkin lymphoma
Hodgkin lymphoma
Autologous stem cell transplantation
Chimeric antigen receptor-modified T cells

Description of Other Expertise

Clinical operations
Quality improvement
Patient safety

Description of Research Expertise

Double-hit B cell lymphoma
MYC-altered B cell lymphoma
Diffuse large B cell lymphoma
High grade B cell lymphoma

Selected Publications

Schneider, Michael, Landsburg, Daniel: The role of pathologic testing in the diagnosis and management of patients with diffuse large B cell lymphoma: a narrative review. Annals of Lymphoma 8, 2024.

Landsburg DJ, Morrissette JJ, Nasta SD, Barta SK, Schuster SJ, Svoboda J, Chong EA, Bagg A.: TP53 mutations predict for poor outcomes in patients with newly-diagnosed aggressive B cell lymphomas in the current era. Blood Adv 7: 7243-7253, Oct 2023.

Landsburg DJ, Nasta SD, Svoboda J, Gerson JN, Schuster SJ, Barta SK, Chong EA, Difilippo H, Weber E, Cunningham K, Catania C, Garfall AL, Stadtmauer EA, Frey NV, Porter DL.: Survival outcomes for patients with relapsed/refractory aggressive B cell lymphomas following receipt of high dose chemotherapy/autologous stem transplantation and/or chimeric antigen receptor-modified T cells. Transplant Cell Ther May 2023.

Landsburg DJ, Morrissette JJD, Schuster SJ, Nasta SD, Gerson JN, Barta SK, Svoboda J, Chong EA, Lim MS.: Mutation analysis performed on tumor biopsies from patients with newly-diagnosed germinal center aggressive B cell lymphomas. Oncotarget 13: 1237-1244, Nov 2022.

Landsburg DJ, Nasta SD, Gerson JN, Svoboda J, Chong EA, Schuster SJ, Barta SK, Robinson KW, Hughes ME.: Time-to-response for patients with relapsed/refractory diffuse large B cell and high grade B cell lymphoma treated with polatuzumab-based therapy. Leuk Lymphoma Aug 2021.

Landsburg DJ, Barta SK, Ramchandren R, Batlevi C, Iyer S, Kelly K, Micallef IN, Smith SM, Stevens DA, Alvarez M, Califano A, Shen Y, Bosker G, Parker J, Soikes R, Martinez E, von Roemeling R, Martell RE, Oki Y.: Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses. Br J Haematol Aug 2021.

Landsburg, D. J., Koike, A., Nasta, S. D., Svoboda, J., Schuster, S. J., Wasik, M. A., Caponetti, G. C.: Patterns of immune checkpoint protein expression in MYC-overexpressing aggressive B-cell non-Hodgkin lymphomas. Cancer Immunol Immunother Aug 28 2020 Notes: doi: 10.1007/s00262-020-02708-3.

Ayers, E. C., Margolis, D., Landsburg, D. J.: Real World Outcomes in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Receiving Palliative Intent Therapies. Clin Lymphoma Myeloma Leuk 2020 Notes: PMID: 32576502.

Frosch, Z. A. K., Landsburg, D. J.: Molecular Risk Stratification in Aggressive B-Cell Lymphomas. J Clin Oncol 38(18): 2014-2017, Jun 2020.

Landsburg, D. J., Ayers, E. C., Bond, D. A., Maddocks, K. J., Karmali, R., Behdad, A., Curry, M., Wagner-Johnston, N. D., Modi, D., Ramchandren, R., Assouline, S. E., Faramand, R., Chavez, J. C., Torka, P., Mier Hicks, A., Medeiros, L. J., Li, S.: Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy. Br J Haematol 189(2): 313-317, 2020.

Ayers, E. C., Li, S., Medeiros, L. J., Bond, D. A., Maddocks, K. J., Torka, P., Mier Hicks, A., Curry, M., Wagner-Johnston, N. D., Karmali, R., Behdad, A., Fakhri, B., Kahl, B. S., Churnetski, M. C., Cohen, J. B., Reddy, N. M., Modi, D., Ramchandren, R., Howlett, C., Leslie, L. A., Cytryn, S., Diefenbach, C. S., Faramand, R., Chavez, J. C., Olszewski, A. J., Liu, Y., Barta, S. K., Mukhija, D., Hill, B. T., Ma, H., Amengual, J. E., Nathan, S., Assouline, S. E., Orellana-Noia, V. M., Portell, C. A., Chandar, A., David, K. A., Giri, A., Hess, B. T., Landsburg, D. J.: Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. Cancer 126(2): 293-303, Jan 2020.

back to top
Last updated: 06/02/2024
The Trustees of the University of Pennsylvania